Hans Biomed Corp
KOSDAQ:042520
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hans Biomed Corp
Total Liabilities & Equity
Hans Biomed Corp
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hans Biomed Corp
KOSDAQ:042520
|
Total Liabilities & Equity
₩141.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Celltrion Inc
KRX:068270
|
Total Liabilities & Equity
₩22.3T
|
CAGR 3-Years
56%
|
CAGR 5-Years
35%
|
CAGR 10-Years
24%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Liabilities & Equity
₩3T
|
CAGR 3-Years
11%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Liabilities & Equity
₩73.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Liabilities & Equity
₩698.7B
|
CAGR 3-Years
42%
|
CAGR 5-Years
34%
|
CAGR 10-Years
33%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Liabilities & Equity
₩280.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Hans Biomed Corp
Glance View
Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-10-09. The firm mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.
See Also
What is Hans Biomed Corp's Total Liabilities & Equity?
Total Liabilities & Equity
141.2B
KRW
Based on the financial report for Dec 31, 2025, Hans Biomed Corp's Total Liabilities & Equity amounts to 141.2B KRW.
What is Hans Biomed Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
12%
Over the last year, the Total Liabilities & Equity growth was 19%.
